UB Paderborn / Katalog / Suche / in CDI

ERROR: Record not found

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

Osteoarthritis and cartilage, 2017-10, Vol.25 (10), p.1598-1606

2017

Volltextzugriff (PDF)

Treating rheumatoid arthritis to target: recommendations of an international task force

Annals of the Rheumatic Diseases, 2010-04, Vol.69 (4), p.631-637

2010

Volltextzugriff (PDF)

A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis

Osteoarthritis and cartilage, 2021-05, Vol.29 (5), p.654-666

2021

Volltextzugriff (PDF)

AB0416 Estimating the short-term costs associated with non-medical switching in rheumatic diseases

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1372

2018

Volltextzugriff (PDF)

FRI0534 Radiographic outcomes were associated with pain and function responses: post-hoc analysis from a phase 2 study of a wnt pathway inhibitor, sm04690, for knee osteoarthritis treatment

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.793

2018

Volltextzugriff (PDF)

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011

Annals of the rheumatic diseases, 2012-04, Vol.71 (Suppl 2), p.i2-i45

2012

Volltextzugriff (PDF)

SAT0586 Results from a 52 week randomised, double-blind, placebo-controlled, phase 2 study of a novel, wnt pathway inhibitor (SM04690) for knee osteoarthritis treatment

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1146

2018

Volltextzugriff (PDF)

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

Annals of the rheumatic diseases, 2010-01, Vol.69 (Suppl 1), p.i2-i29

2010

Volltextzugriff (PDF)

THU0337 Lower-Dose Solumatrix® Indomethacin: Combined Safety Data from Two Phase 3 Studies in Patients with Acute Pain following Elective Surgery

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.298

2014

Volltextzugriff (PDF)

THU0336 Lower-Dose Solumatrix® Indomethacin Efficacy in Acute Pain: Results from Two Phase 3 Studies

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.298-298

2014

Volltextzugriff (PDF)

A Phase 3 study of lower-dose diclofenac submicron particle capsules demonstrates effective pain relief in patients with osteoarthritis

Osteoarthritis and cartilage, 2013-04, Vol.21, p.S267-S267

2013

Volltextzugriff (PDF)

SAT0139 Analysis of Outcomes After Non-Medical Switching of Anti–Tumor Necrosis Factor Agents

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.701-701

2015

Volltextzugriff (PDF)

Solumatrix diclofenac safety in older patients with osteoarthritis pain

Osteoarthritis and cartilage, 2015-04, Vol.23, p.A335-A336

2015

Volltextzugriff (PDF)

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

Annals of the rheumatic diseases, 2011-03, Vol.70 (Suppl 1), p.i2-i36

2011

Volltextzugriff (PDF)

AB0460 Long-term drug survival of etanercept vs other tnf inhibitor therapies in patients with rheumatoid arthritis

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1391

2018

Volltextzugriff (PDF)

Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone

Scandinavian journal of rheumatology, 2015-09, Vol.44 (5), p.354-358

2015

Volltextzugriff (PDF)

Low-dose solumatrix meloxicam demonstrates low systemic exposure and efficacy in patients with osteoarthitis pain in clinical studies

Osteoarthritis and cartilage, 2015-04, Vol.23, p.A324-A325

2015

Volltextzugriff (PDF)

Low-dose SoluMatrix meloxicam results in clinically meaningful improvements in pain in a phase 3 study of patients with osteoarthritis

Osteoarthritis and cartilage, 2016-04, Vol.24, p.S419-S420

2016

Volltextzugriff (PDF)

Solumatrix meloxicam safety in older patients with osteoarthritis pain

Osteoarthritis and cartilage, 2016-04, Vol.24, p.S188-S188

2016

Volltextzugriff (PDF)

THU0126 Dose Titration of Biologics for The Treatment of Rheumatoid Arthritis and Ankylosing Spondylitis: A Systematic Literature Review

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.225

2016

Volltextzugriff (PDF)

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

Annals of the rheumatic diseases, 2008-12, Vol.67 (Suppl 3), p.iii2-iii25

2008

Volltextzugriff (PDF)

(380) A novel application of the Medication Event Monitoring System (MEMS) to track rescue medication use in a phase 3 study of low-dose SoluMatrix meloxicam in patients with osteoarthritis (OA) pain

The journal of pain, 2016-04, Vol.17 (4), p.S70-S70

2016

Volltextzugriff (PDF)

THU0200 Lower-Dose Solumatrix® Meloxicam: Efficacy and Safety in A Phase 3 Study in Adults with Osteoarthritis Pain

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.250-251

2014

Volltextzugriff (PDF)

Diclofenac submicron particle capsules demonstrate early and sustained acute pain relief in a phase 3 study in patients following bunionectomy surgery

Osteoarthritis and cartilage, 2013-04, Vol.21, p.S291-S291

2013

Volltextzugriff (PDF)

SAT0428 Safety, Clinical and Imaging Outcomes of A Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in The Treatment of Osteoarthritis of The Knee: Exploratory Analysis of Results from A 24 Week, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.826-826

2016

Volltextzugriff (PDF)

1 – 25 von 208

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(170)
Mit Volltextzugriff
(137)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(208)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(121)
Science & Technology
(104)
Life Sciences & Biomedicine
(102)
Rheumatology
(68)
Female
(44)
Male
(39)
Biological And Medical Sciences
(30)
Adult
(29)
Medical Sciences
(29)
Middle Aged
(28)
Rheumatoid Arthritis
(26)
Arthritis, Rheumatoid - Drug Therapy
(24)
United States
(23)
Antirheumatic Agents - Therapeutic Use
(21)
General & Internal Medicine
(21)
Medicine, General & Internal
(21)
Aged
(19)
Diseases Of The Osteoarticular System
(18)
Treatment Outcome
(18)
Osteoarthritis
(17)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

Treating rheumatoid arthritis to target: recommendations of an international task force

A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis

AB0416 Estimating the short-term costs associated with non-medical switching in rheumatic diseases

FRI0534 Radiographic outcomes were associated with pain and function responses: post-hoc analysis from a phase 2 study of a wnt pathway inhibitor, sm04690, for knee osteoarthritis treatment

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011

SAT0586 Results from a 52 week randomised, double-blind, placebo-controlled, phase 2 study of a novel, wnt pathway inhibitor (SM04690) for knee osteoarthritis treatment

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

THU0337 Lower-Dose Solumatrix® Indomethacin: Combined Safety Data from Two Phase 3 Studies in Patients with Acute Pain following Elective Surgery

THU0336 Lower-Dose Solumatrix® Indomethacin Efficacy in Acute Pain: Results from Two Phase 3 Studies

A Phase 3 study of lower-dose diclofenac submicron particle capsules demonstrates effective pain relief in patients with osteoarthritis

SAT0139 Analysis of Outcomes After Non-Medical Switching of Anti–Tumor Necrosis Factor Agents

Solumatrix diclofenac safety in older patients with osteoarthritis pain

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

AB0460 Long-term drug survival of etanercept vs other tnf inhibitor therapies in patients with rheumatoid arthritis

Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone

Low-dose solumatrix meloxicam demonstrates low systemic exposure and efficacy in patients with osteoarthitis pain in clinical studies

Low-dose SoluMatrix meloxicam results in clinically meaningful improvements in pain in a phase 3 study of patients with osteoarthritis

Solumatrix meloxicam safety in older patients with osteoarthritis pain

THU0126 Dose Titration of Biologics for The Treatment of Rheumatoid Arthritis and Ankylosing Spondylitis: A Systematic Literature Review

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

(380) A novel application of the Medication Event Monitoring System (MEMS) to track rescue medication use in a phase 3 study of low-dose SoluMatrix meloxicam in patients with osteoarthritis (OA) pain

THU0200 Lower-Dose Solumatrix® Meloxicam: Efficacy and Safety in A Phase 3 Study in Adults with Osteoarthritis Pain

Diclofenac submicron particle capsules demonstrate early and sustained acute pain relief in a phase 3 study in patients following bunionectomy surgery

SAT0428 Safety, Clinical and Imaging Outcomes of A Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in The Treatment of Osteoarthritis of The Knee: Exploratory Analysis of Results from A 24 Week, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

Suchergebnisse filtern